Table 1.
Efficacy of some single or combination vaccines tested against Fasciola hepatica (Modified from [15]).
| Antigen | Source | Host | Schedule a | Adjuvant | Efficacy b (%) |
|---|---|---|---|---|---|
| FhCL | Adult E/S | Cattle | 10–500 μg × 3 | FCA/FIA | 38.2–69.5 |
| 200 μg × 3 | 42.5 | ||||
| Sheep | 100 μg × 2 | 33 | |||
| Recombinant | Cattle | 200 μg × 2 | Montanide c | 47.2 | |
| Montanide d | 49.2 | ||||
| Goat | 100 μg × 2 | Quil A | 0 | ||
| 38.7 | |||||
| 0 | |||||
| Montanide c | 0 | ||||
| Mimotope | Goat | 1 × 1013 pp | Quil A | 46.9–79.5 | |
| FhCL1 + FhHb | Adult E/S | Cattle | 200 μg × 3 | FCA/FIA | 51.9 |
| FhCL2 | Sheep | 100 μg × 2 | FCA/FIA | 34 | |
| FhCL2 + FhHb | Cattle | 200 μg × 3 | FCA/FIA | 72.4 | |
| FCA/FIA | 72.4 | ||||
| FIA | 11.2 | ||||
| FCA/FIA | 29 | ||||
| FhCL1 + FhCL2 | Sheep | 100 μg × 2 | FCA/FIA | 60 | |
| Cattle | 200 μg × 3 | FCA/FIA | 55 | ||
| FhCL1 + FhCL2 + FhLAP Adult E/S | SOM | Sheep | 100 μg × 2 | FCA/FIA | 79 |
| FhCL1 + Prx + Sm14 | Recombinant | Goat | 100 μg × 2 | Quil A | 10.1 |
| FhLAP | Adult Som | Sheep | 100 μg × 2 | FCA/FIA | 89.6 |
| Recombinant | Rabbit | 100 μg × 2 | FCA/FIA | 78 | |
| Sheep | 100 μg × 2 | FCA/FIA | 83.8 | ||
| Alum | 86.7 | ||||
| Adyuvac | 74.4 | ||||
| DEAE-D | 49.8 | ||||
| Ribi | 49.5 | ||||
| FhPrx | Recombinant | Goat | 100 μg × 2 | Quil A | 33.1 |
| 33.1 |
FhCL1, F. hepatica cathepsin L1; FhCL2, F. hepatica cathepsin L2; FhHb, F. hepatica haemoglobin; FhLAP, F. hepatica leucine aminopeptidase; FhPrx, F. hepatica peroxiredoxin; Sm14, Schistosoma mansoni 14-kDa cytoplasmic fatty acid binding protein; Adult E/S or SOM, F. hepatica adult worm excreted/secreted or somatic products; Recombinant, recombinant protein; FCA/FIA, Freund’s complete/incomplete adjuvant; DEAE-D, Diethylaminoethyl-Dextran. a Vaccination dose (μg, micrograms; pp, phage particles number) and boosts number. b Reduction of worm numbers in vaccinated and infected animals, compared with infected and non-vaccinated animals. c Montanide ISA70VG. d Montanide ISA206VG. For further details of each vaccine trial, see Reference [15].